BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18798222)

  • 1. Breast cancer special types: why bother?
    Reis-Filho JS; Lakhani SR
    J Pathol; 2008 Dec; 216(4):394-8. PubMed ID: 18798222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F; Reis-Filho JS
    Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic molecular classification of breast cancers based on gene expression profiling].
    Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological types of breast cancer: how special are they?
    Weigelt B; Geyer FC; Reis-Filho JS
    Mol Oncol; 2010 Jun; 4(3):192-208. PubMed ID: 20452298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histopathologic diagnosis of luminal and basal type breast cancer].
    Sarcević B
    Acta Med Croatica; 2008 Oct; 62(4):427-30. PubMed ID: 19205420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
    Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
    Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis.
    Weigelt B; Kreike B; Reis-Filho JS
    Breast Cancer Res Treat; 2009 Sep; 117(2):273-80. PubMed ID: 18815879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model.
    Rhee DK; Park SH; Jang YK
    Genomics; 2008 Dec; 92(6):419-28. PubMed ID: 18804527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological and molecular types of breast cancer: is there a unifying taxonomy?
    Weigelt B; Reis-Filho JS
    Nat Rev Clin Oncol; 2009 Dec; 6(12):718-30. PubMed ID: 19942925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarrays in breast cancer research and clinical practice--the future lies ahead.
    Gruvberger-Saal SK; Cunliffe HE; Carr KM; Hedenfalk IA
    Endocr Relat Cancer; 2006 Dec; 13(4):1017-31. PubMed ID: 17158752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.
    Marchiò C; Iravani M; Natrajan R; Lambros MB; Savage K; Tamber N; Fenwick K; Mackay A; Senetta R; Di Palma S; Schmitt FC; Bussolati G; Ellis LO; Ashworth A; Sapino A; Reis-Filho JS
    J Pathol; 2008 Aug; 215(4):398-410. PubMed ID: 18484683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression array technology in the diagnosis and treatment of breast cancer.
    Jeffrey SS; Fero MJ; Børresen-Dale AL; Botstein D
    Mol Interv; 2002 Apr; 2(2):101-9. PubMed ID: 14993355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
    Brenton JD; Carey LA; Ahmed AA; Caldas C
    J Clin Oncol; 2005 Oct; 23(29):7350-60. PubMed ID: 16145060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial biomarker expression in breast cancer.
    Rakha EA; Reis-Filho JS; Ellis IO
    Breast Cancer Res Treat; 2010 Apr; 120(2):293-308. PubMed ID: 20107892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of breast cancer patients by gene expression profiling.
    Ahr A; Holtrich U; Solbach C; Scharl A; Strebhardt K; Karn T; Kaufmann M
    J Pathol; 2001 Oct; 195(3):312-20. PubMed ID: 11673828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Microarray technology--potential in cancer research].
    Forus A; Sørlie T; Børresen-Dale AL; Myklebost O
    Tidsskr Nor Laegeforen; 2001 Sep; 121(21):2498-503. PubMed ID: 11875927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
    J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.